Table 2.
Clinico-pathological features of ICC using Kaplan-Meier-method for Recurrence free Survival (RFS). Intratumoral
| Parameter | N | of total | in % | estimated median recurrence free Survival (months) | Range (months) | P |
|---|---|---|---|---|---|---|
| Age at Resection | Mean 67 years | 69 | 28 to 86 | |||
| <70 | 49 | 0.55 | 55.06 | 17.03 | 10.27 to 26.23 | |
| ≥70 | 40 | 0.45 | 44.94 | 24.07 | 12.10 to 38.63 | 0.44 |
| Sex | ||||||
| Female | 48 | 0.54 | 53.93 | 19.53 | 11.10 to 33.23 | |
| Male | 41 | 0.46 | 46.07 | 13.23 | 9.37 to 37.50 | 0.56 |
| Ethnicity | ||||||
| Caucasian | 74 | 0.83 | 83.15 | 19.33 | 11.10 to 31.77 | |
| Black | 4 | 0.04 | 4.49 | 15.13 | 0.10 to NA | |
| Asian | 9 | 0.10 | 10.11 | 19.53 | 9.37 to NA | |
| Hispanic | 1 | 0.01 | 1.12 | NA | NA | |
| Not reported | 1 | 0.01 | 1.12 | NA | NA | 0.74 |
| chronic Hepatitis B/C-virus infection | ||||||
| Yes | 8 | 0.09 | 8.99 | 14.07 | 11.93 to NA | |
| No | 57 | 0.64 | 64.04 | 17.03 | 10.27 to 33.23 | |
| Not tested | 24 | 0.27 | 26.97 | 19.33 | 10 to NA | 0.90 |
| Clinical PSC | ||||||
| Yes | 3 | 0.03 | 3.37 | 15.13 | 13 to NA | |
| No | 86 | 0.97 | 96.63 | 19.53 | 11.10 to 28.63 | 0.37 |
| Tumorsize | Mean: 5.89 cm | 5.60 | 1.80 to 13.50 | |||
| < 5.89 cm | 48 | 0.54 | 53.93 | 24.30 | 15.13 to 38.63 | |
| ≥ 5.89 cm | 41 | 0.46 | 46.07 | 10.20 | 7.93 to 27.30 | 0.74 |
| T-Classification | ||||||
| T1 | 35 | 0.39 | 39.33 | 20.60 | 13 to NA | |
| T2 | 44 | 0.49 | 49.44 | 17.03 | 9.37 to 31.77 | |
| T3 | 7 | 0.08 | 7.87 | 10 | 8.23 to NA | |
| T4 | 3 | 0.03 | 3.37 | 7.27 | 3.17 to NA | 0.23 |
| N-Classification | ||||||
| N+ | 18 | 0.20 | 20.22 | 8.23 | 5.73 to 24.30 | |
| N0 | 40 | 0.45 | 44.94 | 20.60 | 17.43 to 50.40 | |
| No lymph nodes resected | 31 | 0.35 | 34.83 | 17.03 | 11.93 to NA | <0.001* |
| AJCC 8th edition stage | ||||||
| I | 33 | 0.37 | 37.08 | 24.37 | 14.07 to NA | |
| II | 29 | 0.33 | 32.58 | 24.07 | 15.13 to 50.40 | |
| III | 27 | 0.30 | 30.34 | 8.23 | 6.20 to 24.30 | <0.001* |
| Lymphangioinvasion (L) | ||||||
| L+ | 45 | 0.51 | 50.56 | 12.120 | 8.23 to 24.30 | |
| L0 | 44 | 0.49 | 49.44 | 24.37 | 14.07 to NA | 0.01* |
| Satellite Nodule Mass | ||||||
| Yes | 14 | 0.16 | 15.73 | 13.23 | 5.33 to NA | |
| No | 75 | 0.84 | 84.27 | 20.60 | 12.10 to 33.23 | 0.16 |
| Capsule Involvement | ||||||
| Yes | 9 | 0.10 | 10.11 | 8.40 | 8.23 to NA | |
| No | 80 | 0.90 | 89.89 | 19.53 | 13 to 28.63 | 0.27 |
| Periductal infiltrating type | ||||||
| Yes | 8 | 0.09 | 8.99 | 17.03 | 6.20 to NA | |
| No | 62 | 0.70 | 69.66 | 19.53 | 12.10 to 38.63 | |
| Not reported | 19 | 0.21 | 21.35 | 19.53 | 7.63 to NA | 0.25 |
| Adjuvant Radiotherapy | ||||||
| Yes | 33 | 0.37 | 37.08 | 9.37 | 7.63 to 20.60 | |
| No | 56 | 0.63 | 62.92 | 24.30 | 17.43 to 38.63 | 0.01* |
| Tumor budding peritumoral* | ||||||
| low (0-4/0.785mm²) | 37 | 0.42 | 41.57 | 32.68 | 23.58 to 71.40 | |
| intermediate (5-9/0.785mm²) | 37 | 0.42 | 41.57 | 7.97 | 6.74 to 16.90 | |
| high (≥10/0.785mm²) | 6 | 0.07 | 6.74 | 9.87 | 6.97 to NA | <0.001* |
| Tumor budding intratumoral | ||||||
| low (0-4/0.785mm²) | 31 | 0.35 | 34.83 | 32.68 | 25.39 to 48.80 | |
| Intermediate (5-9/0.785mm²) | 35 | 0.39 | 39.33 | 14.65 | 8.13 to 65.20 | |
| high (≥10/0.785mm²) | 23 | 0.26 | 25.84 | 7.61 | 6 to 16.90 | <0.001* |
| Tumor budding compiled | ||||||
| low (0-4/0.785mm²) | 26 | 0.29 | 29.21 | 32.16 | 25.39 to NA | |
| Intermediate (5-9/0.785mm²) | 38 | 0.43 | 42.70 | 13.61 | 9.06 to 42 | |
| High (≥10/0.785mm²) | 25 | 0.28 | 28.09 | 8.92 | 6.90 to 19 | 0.003* |
| NA = Not available *P<0.05 | ||||||
* Tumor budding peritumoral was compiled at the tumor host interface. In 9/89 patients, corresponding tissue samples were not available. Therefore, the number of patients at Tumor budding peritumoral differs from the other listed clinico-pathological parameters.